Natriuretic Peptide-Guided Therapy for Heart Failure

• Mentz Robert J.

  Department of Cardiology, Duke Clinical Research Institute

• Felker G. Michael

  Department of Cardiology, Duke Clinical Research Institute

抄録

Chronic heart failure (HF) remains a major medical problem in the developed world, with rapidly rising prevalence, substantial morbidity, and high costs. The concept of titrating chronic HF therapies using physiologic markers, so called "biomarker guided therapy (BGT)", has become an area of substantial interest in HF given the underutilization of evidence-based medications and suboptimal outcomes with current management strategies. Several recent trials of BGT have had mixed results, with some demonstrating improved outcomes and others showing no benefit. The heterogeneity of patient populations compounded by the lack of standardized BGT algorithms and trial endpoints has complicated interpretation of these results. This article reviews the rationale, accumulated data, and unanswered questions for BGT in chronic HF. (Circ J 2011; 75: 2031-2037)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 75 (9), 2031-2037, 2011

  一般社団法人 日本循環器学会

キーワード

• Biomarker-guided therapy
• Heart failure
• Natriuretic peptides

詳細情報

• CRID: 1390282680080388736
• NII論文ID: 10029338994
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-11-0660
• COI: 1:CAS:528:DC%2BC3MXht1Cjsb7I
• ISSN: 13474820
• ISSN: 13469843
• PubMed: 21791868
• Web Site: http://www.jstage.jst.go.jp/article/circj/75/9/75_CJ-11-0660/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012074565
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可